Recursion Pharmaceuticals, Inc.
MX ˙ BMV ˙ US75629V1044
SecurityMX:RXRX / Recursion Pharmaceuticals, Inc.
InstitutionStifel Financial Corp
Latest Disclosed Ownership776,928 shares
Latest Disclosed Value $ 2,385,190
Stifel Financial Corp reports 31.65% increase in ownership of RXRX / Recursion Pharmaceuticals, Inc.

On May 12, 2026 - Stifel Financial Corp filed a 13F-HR form disclosing ownership of 776,928 shares of Recursion Pharmaceuticals, Inc. (MX:RXRX) valued at $2,385,190 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 590,148 shares of Recursion Pharmaceuticals, Inc.. This represents a change in shares of 31.65% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-12 2026-03-31 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 776,928 186,780 31.65 2,385 -1.16 0.0005
2026-02-13 2025-12-31 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 590,148 147,353 33.28 2,414 11.71 0.0022
2025-11-12 2025-09-30 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 442,795 186,703 72.90 2,161 66.80 0.0020
2025-08-14 2025-06-30 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 256,092 68,833 36.76 1,296 30.81 0.0013
2025-05-14 2025-03-31 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 187,259 27,372 17.12 991 -8.33 0.0011
2025-02-13 2024-12-31 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 159,887 -2,091 -1.29 1,081 1.22 0.0011
2024-11-14 2024-09-30 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 161,978 53,103 48.77 1,067 30.76 0.0011
2024-08-13 2024-06-30 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 108,875 64,466 145.16 817 84.62 0.0009
2024-05-14 2024-03-31 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 44,409 17,220 63.33 443 64.93 0.0005
2024-02-12 2023-12-31 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 27,189 27,189 268 0.0003
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.